[Federal Register Volume 81, Number 88 (Friday, May 6, 2016)]
[Notices]
[Pages 27472-27473]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-10728]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Importer of Controlled Substances Registration: Sharp Clinical 
Services, Inc.

ACTION: Notice of registration.

-----------------------------------------------------------------------

SUMMARY: Sharp Clinical Services, Inc. applied to be registered as an 
importer of a certain basic class of controlled substance. The Drug 
Enforcement Administration (DEA) grants Sharp Clinical Services, Inc. 
registration as an importer of this controlled substance.

SUPPLEMENTARY INFORMATION: By notice dated January 4, 2016, and 
published in the Federal Register on January 11, 2016, 81 FR 1207, 
Sharp Clinical Services, Inc., 300 Kimberton Road, Phoenixville, 
Pennsylvania 19460 applied to be registered as an importer of a certain 
basic class of controlled substance. No comments or objections were 
submitted for this notice.
    The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 
958(a) and determined that the registration of Sharp Clinical Services, 
Inc. to import the basic class of controlled substance is consistent 
with the public interest and with United States obligations under 
international treaties, conventions, or protocols in effect on May 1, 
1971. The DEA investigated the company's

[[Page 27473]]

maintenance of effective controls against diversion by inspecting and 
testing the company's physical security systems, verifying the 
company's compliance with state and local laws, and reviewing the 
company's background and history.
    Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in 
accordance with 21 CFR 1301.34, the above-named company is granted 
registration as an importer of marihuana (7360), a basic class of 
controlled substance listed in schedule I.
    The company plans to import finished pharmaceutical products 
containing cannabis extracts in dosage form for clinical trial studies.
    This compound is listed under drug code 7360. No other activity for 
this drug code is authorized for this registration. Approval of permits 
applications will occur only when the registrant's business activity is 
consistent with what is authorized under 21 U.S.C. 952(a)(2). 
Authorization will not extend to the import of FDA approved or non-
approved finished dosage forms for commercial sale.

    Dated: April 29, 2016.
Louis J. Milione,
Deputy Assistant Administrator.
[FR Doc. 2016-10728 Filed 5-5-16; 8:45 am]
 BILLING CODE 4410-09-P